Trial Profile

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer; Gastric cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

27 Mar 2024 Status changed from active, no longer recruiting to completed.
08 Mar 2024 Planned End Date changed from 8 Apr 2024 to 15 Mar 2024.
08 Mar 2024 Planned primary completion date changed from 8 Apr 2024 to 15 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com